J. Paxton

发表

Plasma pharmacokinetics of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial

B. Baguley, B. Evans, P. Kestell, 1999, Cancer Chemotherapy and Pharmacology.

This study was conducted under the auspices of the Cancer Research Campaign's Phase I/II Committee

B. Baguley, B. Evans, P. Kestell, 1999 .

Topics on Drug Metabolism

J. Paxton, 2012 .

Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion

S. Ganta, B. Baguley, S. Garg, 2009, Journal of drug targeting.

Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug

Hongtao Xu, J. Paxton, Zimei Wu, 2015, Pharmaceutical Research.

Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2).

Yan Li, N. Birch, A. Scheepens, 2013, Food chemistry.

Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay.

F. Rowell, J. Ratcliffe, J. Paxton, 1976, Journal of immunological methods.

Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development.

Hongtao Xu, J. Paxton, Zimei Wu, 2014, Journal of pharmaceutical and biomedical analysis.

Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.

L. Whitfield, J. Paxton, S. N. Kim, 1990, Cancer research.

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

L. Wang, B. Baguley, L. Ching, 2009, Investigational New Drugs.

Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion.

S. Ganta, B. Baguley, S. Garg, 2008, International journal of pharmaceutics.

Inter-species variation in the metabolism and inhibition of N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase.

J. Paxton, I. G. Robertson, P. Schofield, 2000, Biochemical pharmacology.

Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.

P. Kestell, J. Paxton, M. Tingle, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Identification and reactivity of the major metabolite (ß-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans

B. Baguley, P. Kestell, J. Paxton, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs

E. Cornford, D. Young, J. Paxton, 2004, Cancer Chemotherapy and Pharmacology.

The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction

S. Brennecke, G. Reid, K. M. Mohankumar, 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Reversible binding of the novel anti‐tumour agent 5,6‐dimethylxanthenone‐4‐acetic acid to plasma proteins and its distribution into blood cells in various species

Shufeng Zhou, P. Kestell, J. Paxton, 2001, The Journal of pharmacy and pharmacology.

ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast.

J. Keelan, D. Evseenko, J. Paxton, 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice

B. Baguley, P. Kestell, J. Paxton, 2010, Cancer Chemotherapy and Pharmacology.

Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles

M. McKeage, J. Paxton, Yan Li, 2015, PloS one.

Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells

G. Reid, J. Paxton, Yan Li, 2011, Cancer Chemotherapy and Pharmacology.

Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro : implications for prediction of metabolic interactions in vivo

P. Kestell, J. Paxton, M. Tingle, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

The xenobiotic transporter ABCG2 plays a novel role in differentiation of trophoblast-like BeWo cells.

J. Keelan, D. Evseenko, J. Paxton, 2007, Placenta.

3'-azido-3'-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta.

M. Mitchell, J. Keelan, R. Helliwell, 2003, Toxicology and applied pharmacology.

6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3

Shufeng Zhou, P. Kestell, J. Paxton, 2002, European Journal of Drug Metabolism and Pharmacokinetics.

Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

P. Kestell, J. Paxton, M. Tingle, 2001, British journal of clinical pharmacology.

Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection

Shufeng Zhou, P. Kestell, J. Paxton, 1999 .

A rapid, sensitive and specific radioimmunoassay for methotrexate.

F. Rowell, J. Paxton, 1977, Clinica chimica acta; international journal of clinical chemistry.

Blood-brain glucose transfer in the mouse

E. Cornford, J. Paxton, R. Elliott, 1993, Neurochemical Research.

Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects

J. Paxton, 1980, Clinical pharmacology and therapeutics.

The binding of amsacrine to human plasma proteins

S. Foote, J. Paxton, J. L. Jurlina, 1986, The Journal of pharmacy and pharmacology.

A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines.

M. Mitchell, J. Keelan, J. Paxton, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Shufeng Zhou, P. Kestell, J. Paxton, 2002, Cancer Chemotherapy and Pharmacology.

Interrelationship between Pharmacokinetics and Metabolism

J. Paxton, 2010 .

5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer Therapy

Shufeng Zhou, B. Baguley, P. Kestell, 2002, Investigational New Drugs.

Measurement of drugs in saliva: a review.

J. Paxton, 1979, Methods and findings in experimental and clinical pharmacology.

Independent Regulation of Apical and Basolateral Drug Transporter Expression and Function in Placental Trophoblasts by Cytokines, Steroids, and Growth Factors

J. Keelan, D. Evseenko, J. Paxton, 2007, Drug Metabolism and Disposition.

Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.

Shufeng Zhou, E. Chan, B. Baguley, 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells

Wenli Zhang, Hongtao Xu, J. Paxton, 2014, Pharmaceutical Research.

Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells

Bill C. Hawkins, J. Paxton, R. Rosengren, 2017, European journal of pharmacology.

Title : Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines , steroids and growth factors

J. Keelan, D. Evseenko, J. Paxton, 2007 .

Predicting Pharmacokinetic Herb-Drug Interactions

M. Huang, Shufeng Zhou, E. Chan, 2004, Drug metabolism and drug interactions.

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia

J. Paxton, J. L. Jurlina, A. Varcoe, 2004, Cancer Chemotherapy and Pharmacology.

The effect of label affinity on the sensitivity and specificity of a hapten radioimmunoassay: a comparison of three [125I]diphenylhydantoin radioligands with the 14C-labelled drug.

F. Rowell, J. Ratcliffe, J. Paxton, 1979, Journal of immunological methods.

The evaluation of a radioimmunoassay for diphenylhydantoin using an iodinated tracer.

F. Rowell, J. Ratcliffe, J. Paxton, 1977, Clinica chimica acta; international journal of clinical chemistry.

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

B. Baguley, P. Kestell, J. Paxton, 2007, Cancer Chemotherapy and Pharmacology.

Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit

G. Rewcastle, B. Baguley, P. Kestell, 1999, Cancer Chemotherapy and Pharmacology.

Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent

B. Baguley, G. Finlay, E. Richardson, 2013, Cancer Chemotherapy and Pharmacology.

INHIBITION OF HUMAN CYP1A2 OXIDATION OF 5,6‐DIMETHYL‐XANTHENONE‐4‐ACETIC ACID BY ACRIDINES: A MOLECULAR MODELLING STUDY

D. Lewis, Shufeng Zhou, P. Kestell, 2005, Clinical and experimental pharmacology & physiology.

Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative.

B. Palmer, J. Paxton, I. G. Robertson, 1991, Biochemical pharmacology.

Modification of a radioimmunoassay procedure for the study of the pharmacokinetics of methotrexate in the rat

J. Paxton, 1979 .

An indication of possible impending toxicity during moderately high dose methotrexate infusions.

H. F. Wood, J. Paxton, E. J. Stephens, 1978, British journal of clinical pharmacology.

Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation

M. McKeage, J. Paxton, P. Galettis, 1999 .

Blood‐Brain Barrier Penetration of Felbamate

E. Cornford, J. Paxton, D. Young, 1992, Epilepsia.

The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino) phenylamino]-4-acridinecarboxamide (CI-921) in the rabbit

J. Hardy, J. Paxton, P. Evans, 2004, Cancer Chemotherapy and Pharmacology.

The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit

S. Foote, J. Paxton, R. M. Singh, 2004, Cancer Chemotherapy and Pharmacology.

Sustained release of a corticosteroid using polymeric implants

T. Miller, J. Paxton, D. Ormrod, 1986, Agents and Actions.

Interactions of Herbs with Cytochrome P450

Min Huang, Anlong Xu, Shufeng Zhou, 2003, Drug metabolism reviews.

Metabolism of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial

B. Baguley, B. Evans, P. Kestell, 1999, Cancer Chemotherapy and Pharmacology.

Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage.

J. Paxton, J W Paxton, 1981, Journal of pharmacological methods.

Drug Transfer and Metabolism by the Human Placenta

J. Keelan, J. Paxton, Michael R Syme, 2004, Clinical pharmacokinetics.

Active transport across the human placenta: impact on drug efficacy and toxicity

J. Keelan, D. Evseenko, J. Paxton, 2006, Expert opinion on drug metabolism & toxicology.

HEPATIC δ-AMINOLÆVULINIC ACID SYNTHETASE IN AN ATTACK OF HEREDITARY COPROPORPHYRIA AND DURING REMISSION

N. Mcintyre, M. Moore, D. Allan, 1971 .

17-Oxosteroid control of porphyrin biosynthesis.

M. Moore, J. Paxton, A. Beattie, 1973, Enzyme.

Effects of Phenytoin on Cognitive‐Motor Performance in Children as a Function of Drug Concentration, Seizure Type, and Time of Medication

M. Aman, S. Turbott, J. Werry, 1994, Epilepsia.

Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).

J. Hardy, V. Harvey, B. Baguley, 1988, Cancer research.

Propranolol disposition after acute myocardial infarction

R. Norris, J. Paxton, 1984 .

Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay.

B. Whiting, J. Paxton, K. Stephen, 1977, British journal of clinical pharmacology.

Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection.

Shufeng Zhou, J. Paxton, Yan Li, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Thalidomide in Cancer Treatment

Shufeng Zhou, P. Kestell, J. Paxton, 2002 .

Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.

B. Baguley, P. Kestell, J. Paxton, 1990, Cancer research.

Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug

Hongtao Xu, J. Paxton, Zimei Wu, 2015, Pharmaceutical Research.

PREDICTING PHARMACOKINETICS AND DRUG INTERACTIONS IN PATIENTS FROM IN VITRO AND IN VIVO MODELS: THE EXPERIENCE WITH 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID (DMXAA), AN ANTI-CANCER DRUG ELIMINATED MAINLY BY CONJUGATION

Shufeng Zhou, P. Kestell, J. Paxton, 2002, Drug metabolism reviews.

Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption.

Abby C Collier, M. Mitchell, J. Keelan, 2002, Human reproduction.

UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.

M. Mitchell, J. Keelan, M. Blumenstein, 2002, Biochemical pharmacology.

Use of whole saliva for bioavailability studies with reference to phenytoin

J. B. Wilcox, J. Paxton, 1980, The Journal of pharmacy and pharmacology.

Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).

Yan Li, J. Cooney, N. Birch, 2014, Molecular nutrition & food research.

The evaluation of a radioimmunoassay for phenothiazines and thioxanthenes using an iodinated tracer.

F. Rowell, J. Paxton, S. Hui, 1979, Journal of immunological methods.

Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer

G. Reid, J. Paxton, Yan Li, 2010, Drug metabolism reviews.

Rat hepatocyte-mediated metabolism of the experimental anti-tumour agent N-[2'-(dimethylamino)ethyl]acridine-4-carboxamide.

J. Paxton, D. Siegers, B. Schlemper, 1993, Xenobiotica; the fate of foreign compounds in biological systems.

Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranes.

J. Keelan, D. Evseenko, J. Paxton, 2007, Placenta.

Comparisonof Three Radioligands , Selenium-75 , Iodine-125 , and Tritium , in the Radioimmunoassayof Methotrexate

F. Rowell, J. Paxton, G. M. Cree, 2004 .

Prevalence of toxic anticonvulsant drug concentrations in mentally retarded persons with epilepsy.

S. Foote, M. Aman, J. Paxton, 1986, American journal of mental deficiency.

The effects of dietary and herbal phytochemicals on drug transporters☆

J. Paxton, Yan Li, Jezrael L. Revalde, 2017, Advanced drug delivery reviews.

The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics.

Jun Lu, J. Paxton, Yan Li, 2012, Current drug metabolism.

Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).

Yan Li, N. Birch, A. Scheepens, 2014, European journal of pharmacology.

Transport of thalidomide by the human intestinal Caco-2 monolayers

Shufeng Zhou, E. Chan, P. Schafer, 2012, European Journal of Drug Metabolism and Pharmacokinetics.

Alpha 1 -acid glycoprotein and binding of basic drugs.

J. Paxton, 1983, Methods and findings in experimental and clinical pharmacology.

Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide

B. Palmer, Q. Ding, B. Baguley, 2002, Cancer Chemotherapy and Pharmacology.

A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide

Shufeng Zhou, L. Ching, P. Kestell, 2001, Cancer Chemotherapy and Pharmacology.

Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide

B. Palmer, B. Baguley, L. Ching, 2000, Cancer Chemotherapy and Pharmacology.

Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.

Shufeng Zhou, B. Baguley, Bruce C Baguley, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Shufeng Zhou, B. Baguley, P. Kestell, 2003, Biochemical pharmacology.

Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.

Shufeng Zhou, P. Kestell, J. Paxton, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

P. Kestell, J. Paxton, R. Chin, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.

P. Kestell, J. Paxton, M. Tingle, 2001, Journal of chromatography. B, Biomedical sciences and applications.

17-Oxosteroid conjugates in plasma and urine of patients with acute intermittent porphyria.

M. Moore, J. Paxton, A. Goldberg, 1974, Clinical science and molecular medicine.

The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs

J. Paxton, Yan Li, 2013, Expert opinion on drug metabolism & toxicology.

Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain.

W. Wilson, W. Pardridge, G. Finlay, 1992, Cancer research.

Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.

Shufeng Zhou, P. Kestell, J. Paxton, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells

Wenli Zhang, Hongtao Xu, J. Paxton, 2014, Pharmaceutical Research.

Effects of Carbamazepine on Psychomotor Performance in Children as a Function of Drug Concentration, Seizure Type, and Time of Medication

M. Aman, S. Turbott, J. Werry, 1990, Epilepsia.

Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent

B. Baguley, M. McKeage, G. Finlay, 2014, Cancer Chemotherapy and Pharmacology.

Effect of Sodium Valproate on Psychomotor Performance in Children as a Function of Dose, Fluctuations in Concentration, and Diagnosis

M. Aman, S. Turbott, J. Werry, 1987, Epilepsia.

Aberrantly high phenytoin concentrations in saliva. Precaution in monitoring phenytoin concentrations in whole saliva.

S. Foote, J. Paxton, 1979, British journal of clinical pharmacology.

Propranolol binding in serum: comparison of methods and investigation of effects of drug concentration, pH, and temperature.

J. Paxton, R. Calder, 1983, Journal of pharmacological methods.

Disposition of fusidic acid during peritoneal dialysis

J. Collins, T. Miller, J. Paxton, 1997 .

High-dose methotrexate therapy--an area of uncertainty.

J. Paxton, 1979, Australian and New Zealand journal of medicine.

Elementary pharmacokinetics in clinical practice. 3: Practical pharmacokinetic applications.

J. Paxton, 1981, The New Zealand medical journal.

Elementary pharmacokinetics in clinical practice 4: genetic, environmental and age influences on pharmacokinetics.

J. Paxton, 1981, The New Zealand medical journal.

Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells

Hongtao Xu, J. Paxton, Zimei Wu, 2016, Pharmaceutical Research.

Oral Bioavailability and Disposition of Phytochemicals

J. Paxton, Yan Li, 2011 .

Human placental glucuronidation and transport of 3'azido-3'-deoxythymidine and uridine diphosphate glucuronic acid.

M. Mitchell, J. Keelan, J. Paxton, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Improving the oral bioavailability of beneficial polyphenols through designed synergies

A. Scheepens, J. Paxton, Kee Tan, 2010, Genes & Nutrition.

Comparison of three radioligands, selenium-75, lodine-125, and tritium, in the radioimmunoassay of methotrexate.

F. Rowell, J. Paxton, G. M. Cree, 1978, Clinical chemistry.

Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine

Hongtao Xu, J. Paxton, Zimei Wu, 2021, Pharmaceutical Research.

Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Shufeng Zhou, B. Baguley, P. Kestell, 2003, Biochemical pharmacology.

Interaction of probenecid with the protein binding of methotrexate.

J. Paxton, 1984, Pharmacology.

Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.

Sanjay Garg, Srinivas Ganta, S. Ganta, 2009, International journal of pharmaceutics.

Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine

D. Ferry, J. Paxton, R. Briant, 2004, European Journal of Clinical Pharmacology.

Development of radioimmunoassays for drugs.

J. Paxton, 1981, Methods and findings in experimental and clinical pharmacology.

Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness.

J. Paxton, R. Briant, 1984, British journal of clinical pharmacology.

High-performance liquid-chromatographic method for the determination of 4'-(9-acridinylamino)methanesulfon-m-anisidide in plasma.

J. Paxton, J. L. Jurlina, 1983, Journal of chromatography.

THE PROTEIN BINDING AND ELIMINATION OF METHOTREXATE AFTER INTRAVENOUS INFUSIONS IN CANCER PATIENTS

J. Paxton, 1982, Clinical and experimental pharmacology & physiology.

Bioavailability of methotrexate: Implications for clinical use

J. Mcvie, J. Stuart, B. Whiting, 2004, Cancer Chemotherapy and Pharmacology.

Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells

Hongtao Xu, J. Paxton, Zimei Wu, 2016, Pharmaceutical Research.

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: THE ALLOMETRIC APPROACH FOR INTERSPECIES SCALING OF PHARMACOKINETICS AND TOXICITY OF ANTI‐CANCER DRUGS

J. Paxton, James W. Paxton, 1995 .

Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.

Yan Li, Bill C. Hawkins, J. Paxton, 2015, Biochemical pharmacology.

Prediction of herb–drug metabolic interactions: a simulation study

Shufeng Zhou, W. Duan, A. Xu, 2005, Phytotherapy research : PTR.

Therapeutic drug monitoring and clinical pharmacokinetics.

J. Paxton, 1981, Australian and New Zealand journal of medicine.

Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics

B. Baguley, P. Kestell, J. Paxton, 2012, Cancer Chemotherapy and Pharmacology.

A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development.

B. Baguley, G. Atwell, P. Kestell, 2012, Journal of pharmaceutical and biomedical analysis.

Tumour profile ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse

P. Kestell, J. Paxton, D. Young, 2004, Cancer Chemotherapy and Pharmacology.

Fluctuations in Salivary Carbamazepine and Carbamazepine‐10,11‐Epoxide Concentrations During the Day in Epileptic Children

M. Aman, J. Werry, J. Paxton, 1983, Epilepsia.

Carbamazepine Determination in Saliva of Children: Enzyme Immunoassay (EMIT®) Versus High Pressure Liquid Chromatography

J. Paxton, 1982, Epilepsia.

Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum

J. Paxton, Roger A Donald, 1980, Clinical pharmacology and therapeutics.

Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse.

B. Palmer, J. Paxton, G. J. Shaw, 1992, Xenobiotica; the fate of foreign compounds in biological systems.

THIOLYTIC CLEAVAGE AND BINDING OF THE ANTITUMOUR AGENT CI-921 IN BLOOD

B. Baguley, P. Kestell, J. Paxton, 1988, Drug metabolism and drug interactions.

Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer

G. Reid, J. Paxton, Yan Li, 2010, Drug metabolism reviews.

Plasma Protein Binding of the Experimental Antitumour Agent Acridine‐4‐carboxamide in Man, Dog, Rat and Rabbit

J. Paxton, I. Robertson, Sean Evans, 1994, The Journal of pharmacy and pharmacology.

Pharmacokinetics and toxicity of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse

E. Cornford, D. Young, P. Kestell, 2004, Cancer Chemotherapy and Pharmacology.

Conformational and chemical requirements for antibody recognition of diphenylhydantoin derivatives.

F. Rowell, J. Paxton, 1976, Immunochemistry.

PLASMA AND BILIARY DISPOSITION OF PIRENZEPINE IN MAN

J. Paxton, S. P. Lee, Y. Choong, 1986, Clinical and experimental pharmacology & physiology.